Information:
Fel:
ID
34393
Beskrivning
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status; ODM derived from: https://clinicaltrials.gov/show/NCT01283386
Länk
https://clinicaltrials.gov/show/NCT01283386
Nyckelord
Versioner (1)
- 2019-01-17 2019-01-17 -
Rättsinnehavare
GSK group of companies
Uppladdad den
17 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Lymphocytic Leukemia, Chronic NCT01283386
Eligibility Lymphocytic Leukemia, Chronic NCT01283386
- StudyEvent: Eligibility
Similar models
Eligibility Lymphocytic Leukemia, Chronic NCT01283386
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
adult patients, 60-70 or >70 years of age
boolean
ID.2
Item
cumulative illness rating scale (cirs) comorbidity score >/=7 if patient is 60-70 years old
boolean
ID.3
Item
previously untreated b-cell chronic lymphocytic leukemia
boolean
ID.4
Item
binet stage b, c or a with progression
boolean
ID.5
Item
ecog performance status 0-2
boolean
ID.6
Item
small-cell lymphoma
boolean
ID.7
Item
autoimmune hemolytic anemia
boolean
ID.8
Item
concomitant malignant disease during enrollment, except for basal cell carcinoma of the skin
boolean
ID.9
Item
chemotherapy for concomitant malignant disease within 12 months prior to study enrollment
boolean
ID.10
Item
richter's syndrome
boolean